DENVER, Aug. 12, 2026 (GLOBE NEWSWIRE) — (247marketnews.com)- The market is serving up several very different stories converging into one high-energy trading session. Rocky Mountain Chocolate Factory (NASDAQ: RMCF) is suddenly in play after disclosing that its board is exploring strategic alternatives that could include a sale, merger or going-private transaction. NeOnc Technologies Holdings (NASDAQ: NTHI) delivered a major clinical catalyst with NEO100 beating the six-month progression-free-survival benchmark by nearly 2.5 times. Meanwhile, Boxlight (NASDAQ: BOXL) is trying to buy itself additional financial runway, while OFA Group (NASDAQ: OFAL) is in the mix after its recent 1-for-10 reverse split, and the tape is packed with the kind of catalysts that can produce outsized moves.
Rocky Mountain Chocolate: Takeover Speculation Sends Stock Soaring
Rocky Mountain Chocolate Factory (NASDAQ: RMCF) may have just handed traders one of the most explosive corporate-action stories of the session. In an August 11 Form 8-K, the company disclosed that its board, with assistance from advisors, is exploring strategic alternatives that could include a possible sale, merger, other business combination or going-private transaction. The company also said it has received expressions of interest from third parties. There is no assurance that a transaction will ultimately occur, but the disclosure dramatically changes the conversation around a stock that had recently been trading near its 52-week low.
The market reaction was immediate. That kind of move illustrates the power of a potential strategic transaction when a small-cap company suddenly becomes a possible acquisition target. The important distinction is that RMCF has not announced a deal; it has announced a strategic review and acknowledged third-party interest.
The timing is particularly interesting because Rocky Mountain has been pursuing a broader transformation strategy. Earlier this year, the company launched an omnichannel initiative designed to expand digital marketplace, delivery and catering opportunities, while also bringing its Nashville Opry Mills location under corporate ownership to test and refine initiatives before wider rollout. The new strategic-alternatives disclosure now creates another potential path to shareholder value and potentially puts the company’s brand, retail footprint, manufacturing capabilities and franchise network into the spotlight for prospective buyers.
NeOnc Technologies Holdings: Brain-Cancer Data Turns Into a Major Market Catalyst
NeOnc (NASDAQ: NTHI) delivered the kind of clinical update that can completely reset the narrative around a small biotechnology company. Its Phase 2a NEO100-01 study produced a 48.9% six-month progression-free survival rate, versus a 20% pre-specified historical benchmark, with the difference statistically significant at p=0.0047. Median overall survival reached approximately 26.09 months, while estimated overall survival was 86.7% at six months, 60.9% at 12 months and 54.1% at 24 months. Five of the 24 patients remained on treatment, including one patient who had remained progression-free for approximately 19 months.
The patient implications may be more important than the trading implications. NEO100 is being studied in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant high-grade glioma, after prior radiation and temozolomide treatment, a population with very limited options. The therapy is administered intranasally at home four times daily, rather than through an infusion, and NeOnc reported no major toxicities across the cohort, with adverse events predominantly low-grade. That combination of potential disease control, durability and tolerability is particularly important in recurrent brain cancer, where treatment burden and cumulative toxicity can become major parts of a patient’s experience.
The data are not the same as an approval, and the study was an open-label Phase 2a trial involving 24 patients, meaning a larger confirmatory study will be needed. But NeOnc now intends to request a Type B meeting with the FDA to discuss a registrational development path. The company has also been expanding NEO100 internationally, including UAE IND authorization covering adult Phase 1 through Phase 2 programs and pediatric studies, while NEO100 carries FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations. For investors, the central question has shifted from whether NEO100 can generate a meaningful signal to how regulators will view the signal and what a potential registrational program could look like.
OFA Group: The Reverse-Split Trade is Still Red-Hot
OFA Group (NASDAQ: OFAL) is a different type of momentum story, but one that fits squarely into the market’s appetite for high-volatility small caps. The company completed a 1-for-10 reverse stock split July 31, reducing its Class A ordinary shares from approximately 26.37 million to approximately 2.64 million.
The reverse split followed a Nasdaq minimum-bid-price problem. OFA had received an additional 180-day compliance period extending through December 7, 2026, after Nasdaq determined that the $1 minimum bid-price requirement was the company’s remaining continued-listing deficiency.
That creates a familiar small-cap setup: fewer shares outstanding after the split, a recently reset trading structure and a stock that can become extremely volatile when momentum traders pile into the name. The reverse split can materially alter trading dynamics. The bigger fundamental question remains whether OFA can build a sustainable business while maintaining Nasdaq compliance. For today, OFAL belongs firmly on the high-volatility side of the market.
Boxlight: $7.5M Financing Buys Time, but Dilution Remains the Question
Boxlight (NASDAQ: BOXL) secured a fresh capital lifeline that could provide up to $7.5 million in gross proceeds, with $5.5 million funded at the initial closing and another $2 million potentially available once a resale registration statement becomes effective, subject to conditions. The company issued 937,500 shares of Series D Convertible Preferred Stock at $8 per share, with each preferred share carrying a $10 stated value. The preferred securities can convert into Class A common stock based on a formula tied to the lowest closing price before conversion, subject to a 4.99% beneficial-ownership limitation.
The company simultaneously established a $15 million equity line with Secure Net Capital that can be accessed over 36 months, again subject to conditions. Boxlight also agreed to issue $150,000 of commitment shares, with the investor able to elect pre-funded warrants in lieu of certain commitment shares. The important takeaway for traders is that the equity line is not an immediate $15 million stock sale, but it gives management another potential source of liquidity. The preferred financing, however, creates potential future dilution if converted into common shares.
That distinction matters because Boxlight’s financing needs are occurring against a difficult financial backdrop. The company previously reported first-quarter revenue of $22.4 million, gross profit of $6.9 million, a $6.5 million net loss and negative adjusted EBITDA of $2.8 million, while debt remained substantial. The new financing is intended for general corporate purposes, including working capital and debt retirement. In other words, Boxlight has bought additional financial oxygen—but investors still need to see whether management can turn that oxygen into improving margins, cash flow and a sustainable business rather than simply extending the runway.
Sources
- Rocky Mountain Chocolate Factory — SEC Form 8-K
- Rocky Mountain Chocolate Factory Investor Relations
- NeOnc Technologies Investor Relations
- NeOnc NEO100 Clinical Update
- OFA Group Nasdaq Reverse-Split Notice
- Boxlight Private Placement Announcement
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For further information, please visit 247mnn.com.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
Media gallery
